Related Experiment Video
Updated: Apr 19, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT trial)
David S Wald1, Jonathan P Bestwick1, Lewis Raiman1
1Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.
Insights
Text messages significantly improved medication adherence for patients taking cardiovascular disease preventive treatments. This simple intervention helped more patients stay on their prescribed blood pressure and lipid-lowering drugs.
Area of Science:
- Cardiology
- Digital Health
- Public Health
Background:
- Medication non-adherence affects one-third of patients prescribed cardiovascular preventive drugs.
- Poor adherence to blood pressure and lipid-lowering medications increases risks for coronary heart disease and stroke.
Purpose of the Study:
- To evaluate the effectiveness of text messaging in improving medication adherence for cardiovascular disease prevention.
Main Methods:
- A randomized trial involving 303 patients prescribed blood pressure and/or lipid-lowering medications.
- Patients were assigned to receive daily, alternate-day, and then weekly text messages for 6 months or a control group.
- Medication adherence and reasons for non-adherence were assessed via patient responses to automated texts.
Main Results:
- Medication adherence improved in the text message group (9% non-adherence) compared to the control group (25% non-adherence).
- Text messages reminded 65% of patients to take their medication, leading 13% to resume treatment after concerns.
Conclusions:
- Text messaging is an effective strategy to enhance medication adherence in patients on cardiovascular preventive treatment.
- This digital health intervention offers a scalable solution to improve cardiovascular disease prevention outcomes.
Background:
About one third of patients prescribed blood pressure or lipid-lowering drugs for the prevention of coronary heart disease and stroke do not take their medication as prescribed. We conducted a randomized trial to evaluate text messaging as a means of improving adherence to cardiovascular disease preventive treatment.
Methods:
303 patients taking blood pressure and/or lipid-lowering medications were randomly assigned to being sent text messages (Text group, 151) or not being sent them (No text group, 152). Texts were sent daily for 2 weeks, alternate days for 2 weeks and weekly thereafter for 22 weeks (6 months overall), using an automated computer programme. Patients were asked to respond on whether they had taken their medication, whether the text reminded them to do so if they had forgotten, and if they had not taken their medication to determine if there was a reason for not doing so. At 6 months, use of medication was assessed.
Results:
Two patients were lost to follow-up, providing data on 301 for analysis. In the No text group 38/151 (25%) took less than 80% of the prescribed regimen (ie. stopped medication completely or took it on fewer than 22 of the last 28 days of follow-up) compared to 14/150 patients (9%) in the Text group - an improvement in adherence affecting 16 per 100 patients (95% CI 7 to 24), p<0.001. The texts reminded 98/151 patients (65%) to take medication on at least one occasion and lead to 20/151 (13%) who stopped taking medication because of concern over efficacy or side-effects, resuming treatment.
Conclusions:
In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease, text messaging improved medication adherence compared with no text messaging.
Trial Registration:
Controlled-Trials.com ISRCTN74757601.
More Related Videos
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Clinical Trials
There are four phases in a clinical trial. A phase one...
Randomized Experiments
Simple randomization
Simple...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Clinical Trials: Overview
Peripheral Artery Disease III: Interprofessional Care

